IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic
Status:
Terminated
Trial end date:
2023-02-10
Target enrollment:
Participant gender:
Summary
This study is a Multicenter, Open-label, Phase II study of ixazomib, plus Pomalidomide and
Dexamethasone regimen (IPD) in RRMM with adverse Genomic Abnormalities.
Phase:
Phase 2
Details
Lead Sponsor:
Intergroupe Francophone du Myelome
Collaborators:
AXONAL Bristol-Myers Squibb Euraxi Pharma Nantes University Hospital QPS Holdings LLC Takeda University Hospital, Grenoble